http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-33929-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b86dbdcfe153c2dfb874aff99d07177 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-74 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C53-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C53-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C55-38 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C55-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C209-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C209-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C209-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C209-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J19-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B61-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-02 |
| filingDate | 1969-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1974-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-33929-B1 |
| titleOfInvention | Adamantanyl alkylamine derivatives and their preparation |
| abstract | 1,274,652. Antidepressant &c. compositions. LILLY INDUSTRIES Ltd. 28 Oct., 1969 [27 Aug., 1968], No. 40968/68. Heading A5B. [Also in Division C2] Pharmaceutical compositions having antidepressant, -Parkinsonism and -motion sickness and appetite suppressant activity comprise, as active ingredient, at least one 1-aminoalkyladamantane of the general formula wherein n is 1 or 2; R<SP>1</SP> is a hydrogen atom or a C 1-4 alkyl group or, when n is 1, R<SP>1</SP> and R<SP>4</SP> together form a methylene group; R<SP>2</SP> is a hydrogen atom or C 1-4 alkyl group or, when n is 1, a C 1-4 hydroxyalkyl or phenyl-C 1- 4 alkyl group, R<SP>3</SP> is a hydrogen atom or a C 1-4 alkyl group or, when R<SP>2</SP> is a hydrogen atom, R<SP>3</SP> is an amidino, pyrimidinyl or C 1-4 alkylpyrimidinyl group, or NR<SP>2</SP>R<SP>3</SP> is a pyrrolidino, piperidino, NC 1-4 alkylpiperazino or N-C 1-4 hydroxyalkylpiperazino group; R<SP>4</SP> is a hydrogen or chlorine atom or a phenyl group or, when n is 1, a bromine atom or cyclohexyl group; R<SP>5</SP> and R<SP>6</SP> are each a hydrogen atom or, when n is 1, a chlorine atom or phenyl group; provided that one of R<SP>4</SP>, R<SP>5</SP> and R<SP>6</SP> is not a chlorine atom and the others are hydrogen atoms or R<SP>4</SP> is not a bromine atom and R<SP>5</SP> and R<SP>6</SP> are hydrogen atoms, when R<SP>7</SP>, R<SP>8</SP> and R<SP>9</SP> are hydrogen atoms, R<SP>1</SP> is a hydrogen atom or a C 1-4 alkyl group, one of R<SP>2</SP> and R<SP>3</SP> is a hydrogen atom and the other is a C 1-4 alkyl group and n is 1; R<SP>7</SP> is a hydrogen or bromine atom or a hydroxyl or -(CH 2 ) n - -CHR a <SP>1</SP>-NR a <SP>2</SP>R a <SP>3</SP> group, wherein n is 1 or 2 and R a <SP>1</SP>, R a <SP>2</SP> and R a <SP>3</SP> are each a hydrogen atom or a C 1-4 alkyl group, or, when n is 1, R<SP>7</SP> is a methyl group; and R<SP>8</SP> and R<SP>9</SP> are each a hydrogen atom or, when n is 1, a methyl group; or pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier.n[GB1274652A] |
| priorityDate | 1968-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.